FENC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fennec Pharmaceuticals Inc (FENC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, unique FDA-approved product with no competition, and positive analyst rating with a significant price target upside make it a compelling investment opportunity. While the technical indicators are mixed, the long-term growth potential outweighs short-term price fluctuations.
The MACD is positive and expanding, suggesting potential bullish momentum. However, the RSI is neutral at 49.278, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are at S1: 5.816 and R1: 6.534, with the current price at 6.3 sitting near the pivot point of 6.175.
FDA approval of Pedmark, the only therapy in its category, with no competition or pipeline threats.
Analyst rating of 'Buy' with a $16 price target, indicating significant upside potential.
Projected 55% annual revenue growth through 2027, one of the highest in the sector.
Recent price decline of -3.08% and bearish moving averages.
Gross margin decline of -4.76% YoY in the latest quarter.
No recent news or significant insider/hedge fund activity.
In Q4 2025, revenue increased by 73.84% YoY to $13,777,000, and net income improved by 141.16% YoY to -$4,787,000. EPS also improved by 114.29% YoY to -0.15. However, gross margin dropped to 87.2%, down -4.76% YoY.
B. Riley initiated coverage with a 'Buy' rating and a $16 price target, citing undervaluation and strong growth potential for Pedmark.
